BioNTech Fields a $1 Billion Buyback and a Moderna Plant Bid While Eyeing a Cancer-Fueled Future

The German biotech group BioNTech is sending two very different signals to the market at once. Its management is busy buying back shares at a pace of up to $1 billion, a classic vote of confidence in its own undervaluation. At the same time, it is shuttering four production sites in Germany and Singapore, leaving roughly 1,860 employees facing redundancy. The contrast could hardly be starker — and it has drawn an opportunistic rival into the frame.

Moderna chief Stéphane Bancel confirmed this week that his company is exploring the acquisition of those disused German facilities in Idar-Oberstein, Marburg and Tübingen, plus a plant in Singapore. Speaking to Handelsblatt, Bancel described the existing infrastructure as a far cheaper alternative to building new capacity. Should a deal with the German government materialise, Moderna intends to take on the affected BioNTech workforce, ensuring a seamless handover.

The planned divestments are not a sign of distress but a deliberate pivot. BioNTech is transforming itself into a pure-play oncology specialist and needs every euro of the €16.8 billion it holds in cash to fund its push into cancer treatments. That war chest is already being deployed aggressively: this year the company expects to spend up to €2.5 billion on R&D, and by the end of 2026 it aims to have 15 pivotal Phase 3 studies under way.

Early clinical momentum is on its side. At the ASCO conference in early June, BioNTech showcased promising data on Pumitamig in non-small cell lung cancer and on Gotistobart in heavily pre-treated ovarian cancer. The PRESERVE-004 study for the latter revealed a complex but instructive dose‑response: patients receiving the lower dose of 1 mg/kg achieved a median overall survival of 18.9 months, compared with just 8.3 months for the higher dose. Such nuances are par for the course in oncology, but they do not diminish the signal.

Another key asset is BNT327, a candidate being developed with Bristol Myers Squibb for lung cancer. BioNTech reported response rates above 60% from a Phase 2 trial, clearing the path for pivotal Phase 3 studies. Later this year, the company plans to file its first US new drug application — for Trastuzumab Pamirtecan in endometrial cancer — while seven more important readouts are expected in the second half of 2026.

Should investors sell immediately? Or is it worth buying BioNTech?

Despite this pipeline progress, the stock has struggled. At current levels around €79 — with one article quoting €78.90 and another €79.10 — shares are roughly 25% below their January high. The weight on the price is largely attributed to the shock announcement in March that co‑founders Ugur Şahin and Özlem Türeci would leave BioNTech at the end of 2026 to launch a new mRNA start‑up. The news triggered a more than 20% sell‑off, and the market has yet to fully shake off that gloom.

Analysts, however, see the sell‑off as overdone. The average price target stands at €107.75, implying upside of more than 36%. Of 19 analysts covering the stock, 14 rate it a buy and none recommend selling. UBS upgraded to “Buy” at the end of May with a target of $135, citing the strength of the ASCO data. The board is already searching for successors and expects to have a binding contract with the founders’ new venture in place by the end of June, giving uncertainty a clear expiry date.

Chart‑wise, the technical picture remains fragile. BioNTech’s shares trade below all key moving averages, with the 200‑day line at €85.49 representing a 7.5% gap above the current price. The March low of €68.35 has offered a floor for now, and the relative strength index of 51.7 suggests the stock is neither overbought nor oversold — effectively stuck in neutral. The $1 billion buy‑back programme, which began on 8 June, is designed to nudge sentiment in the right direction, but so far it has failed to generate a sustained rally.

The next major catalysts are a business briefing on 30 June and second‑quarter results on 4 August. Investors will be looking for concrete details on the potential plant sale to Moderna, as well as any update on the leadership succession. Until the CEO question is resolved, the founder‑departure discount is likely to persist. But with a formidable cash position, a deep clinical pipeline and a buy‑back that signals management’s conviction, the stock may be coiling for a breakout once the fog lifts.